The Potential of Neoagaro-Oligosaccharides as a Treatment of Type II Diabetes in Mice
Type 2 diabetes mellitus (T2DM) accounts for more than 90% of cases of diabetes mellitus, which is harmful to human health. Herein, neoagaro-oligosaccharides (NAOs) were prepared and their potential as a treatment of T2DM was evaluated in KunMing (KM) mice. Specifically, a T2DM mice model was establ...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-09-01
|
| Series: | Marine Drugs |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1660-3397/17/10/541 |
| _version_ | 1828232882347311104 |
|---|---|
| author | Fudi Lin Dongda Yang Yayan Huang Yan Zhao Jing Ye Meitian Xiao |
| author_facet | Fudi Lin Dongda Yang Yayan Huang Yan Zhao Jing Ye Meitian Xiao |
| author_sort | Fudi Lin |
| collection | DOAJ |
| description | Type 2 diabetes mellitus (T2DM) accounts for more than 90% of cases of diabetes mellitus, which is harmful to human health. Herein, neoagaro-oligosaccharides (NAOs) were prepared and their potential as a treatment of T2DM was evaluated in KunMing (KM) mice. Specifically, a T2DM mice model was established by the combination of a high-fat diet (HFD) and alloxan injection. Consequently, the mice were given different doses of NAOs (100, 200, or 400 mg/kg) and the differences among groups of mice were recorded. As a result of the NAOs treatment, the fasting blood glucose (FBG) was lowered and the glucose tolerance was improved as compared with the model group. As indicated by the immunohistochemistry assay, the NAOs treatment was able to ameliorate hepatic macrovesicular steatosis and hepatocyte swelling, while it also recovered the number of pancreatic β-cells. Additionally, NAOs administration benefited the antioxidative capacity in mice as evidenced by the upregulation of both glutathione peroxidase and superoxide dismutase activity and the significant reduction of the malondialdehyde concentration. Furthermore, NAOs, as presented by Western blotting, increased the expression of p-ERK1/2, p-JNK, NQO1, HO-1, and PPARγ, via the MAPK, Nrf2, and PPARγ signaling pathways, respectively. In conclusion, NAOs can be used to treat some complications caused by T2DM, and are beneficial in controlling the level of blood glucose and ameliorating the damage of the liver and pancreatic islands. |
| first_indexed | 2024-04-12T19:28:48Z |
| format | Article |
| id | doaj.art-aeb0247b23e945ec948d1b40432627db |
| institution | Directory Open Access Journal |
| issn | 1660-3397 |
| language | English |
| last_indexed | 2024-04-12T19:28:48Z |
| publishDate | 2019-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Marine Drugs |
| spelling | doaj.art-aeb0247b23e945ec948d1b40432627db2022-12-22T03:19:24ZengMDPI AGMarine Drugs1660-33972019-09-01171054110.3390/md17100541md17100541The Potential of Neoagaro-Oligosaccharides as a Treatment of Type II Diabetes in MiceFudi Lin0Dongda Yang1Yayan Huang2Yan Zhao3Jing Ye4Meitian Xiao5College of Chemical Engineering, Huaqiao University, Xiamen 361021, ChinaCollege of Chemical Engineering, Huaqiao University, Xiamen 361021, ChinaCollege of Chemical Engineering, Huaqiao University, Xiamen 361021, ChinaCollege of Chemical Engineering, Huaqiao University, Xiamen 361021, ChinaCollege of Chemical Engineering, Huaqiao University, Xiamen 361021, ChinaCollege of Chemical Engineering, Huaqiao University, Xiamen 361021, ChinaType 2 diabetes mellitus (T2DM) accounts for more than 90% of cases of diabetes mellitus, which is harmful to human health. Herein, neoagaro-oligosaccharides (NAOs) were prepared and their potential as a treatment of T2DM was evaluated in KunMing (KM) mice. Specifically, a T2DM mice model was established by the combination of a high-fat diet (HFD) and alloxan injection. Consequently, the mice were given different doses of NAOs (100, 200, or 400 mg/kg) and the differences among groups of mice were recorded. As a result of the NAOs treatment, the fasting blood glucose (FBG) was lowered and the glucose tolerance was improved as compared with the model group. As indicated by the immunohistochemistry assay, the NAOs treatment was able to ameliorate hepatic macrovesicular steatosis and hepatocyte swelling, while it also recovered the number of pancreatic β-cells. Additionally, NAOs administration benefited the antioxidative capacity in mice as evidenced by the upregulation of both glutathione peroxidase and superoxide dismutase activity and the significant reduction of the malondialdehyde concentration. Furthermore, NAOs, as presented by Western blotting, increased the expression of p-ERK1/2, p-JNK, NQO1, HO-1, and PPARγ, via the MAPK, Nrf2, and PPARγ signaling pathways, respectively. In conclusion, NAOs can be used to treat some complications caused by T2DM, and are beneficial in controlling the level of blood glucose and ameliorating the damage of the liver and pancreatic islands.https://www.mdpi.com/1660-3397/17/10/541type 2 diabetes mellitusneoagaro-oligosaccharidesMAPKNrf2PPARγ |
| spellingShingle | Fudi Lin Dongda Yang Yayan Huang Yan Zhao Jing Ye Meitian Xiao The Potential of Neoagaro-Oligosaccharides as a Treatment of Type II Diabetes in Mice Marine Drugs type 2 diabetes mellitus neoagaro-oligosaccharides MAPK Nrf2 PPARγ |
| title | The Potential of Neoagaro-Oligosaccharides as a Treatment of Type II Diabetes in Mice |
| title_full | The Potential of Neoagaro-Oligosaccharides as a Treatment of Type II Diabetes in Mice |
| title_fullStr | The Potential of Neoagaro-Oligosaccharides as a Treatment of Type II Diabetes in Mice |
| title_full_unstemmed | The Potential of Neoagaro-Oligosaccharides as a Treatment of Type II Diabetes in Mice |
| title_short | The Potential of Neoagaro-Oligosaccharides as a Treatment of Type II Diabetes in Mice |
| title_sort | potential of neoagaro oligosaccharides as a treatment of type ii diabetes in mice |
| topic | type 2 diabetes mellitus neoagaro-oligosaccharides MAPK Nrf2 PPARγ |
| url | https://www.mdpi.com/1660-3397/17/10/541 |
| work_keys_str_mv | AT fudilin thepotentialofneoagarooligosaccharidesasatreatmentoftypeiidiabetesinmice AT dongdayang thepotentialofneoagarooligosaccharidesasatreatmentoftypeiidiabetesinmice AT yayanhuang thepotentialofneoagarooligosaccharidesasatreatmentoftypeiidiabetesinmice AT yanzhao thepotentialofneoagarooligosaccharidesasatreatmentoftypeiidiabetesinmice AT jingye thepotentialofneoagarooligosaccharidesasatreatmentoftypeiidiabetesinmice AT meitianxiao thepotentialofneoagarooligosaccharidesasatreatmentoftypeiidiabetesinmice AT fudilin potentialofneoagarooligosaccharidesasatreatmentoftypeiidiabetesinmice AT dongdayang potentialofneoagarooligosaccharidesasatreatmentoftypeiidiabetesinmice AT yayanhuang potentialofneoagarooligosaccharidesasatreatmentoftypeiidiabetesinmice AT yanzhao potentialofneoagarooligosaccharidesasatreatmentoftypeiidiabetesinmice AT jingye potentialofneoagarooligosaccharidesasatreatmentoftypeiidiabetesinmice AT meitianxiao potentialofneoagarooligosaccharidesasatreatmentoftypeiidiabetesinmice |